Table 2.
Univariate analysis.
| Phenotypes | p-Value * | ||||
|---|---|---|---|---|---|
| Characteristics | 1 (n = 394) | 2 (n = 962) | 3 (n = 1079) | 4 (n = 236) | |
| Age | 0.055 | ||||
| <55 | 68 (17.3%) | 220 (22.9%) | 244 (22.6%) | 57 (24.2%) | |
| 55–64 | 96 (24.4%) | 229 (23.8%) | 305 (28.3%) | 66 (26.1%) | |
| 65–74 | 128 (32.5%) | 301 (31.3%) | 313 (29.0%) | 68 (28.8%) | |
| ≥75 | 102 (25.9%) | 212 (22.0%) | 217 (20.1%) | 45 (19.1%) | |
| Gender | 0.5 | ||||
| Female | 177 (44.9%) | 452 (47%) | 476 (44.1%) | 101 (42.8%) | |
| Male | 217 (55.1%) | 510 (53%) | 603 (55.9%) | 135 (57.2%) | |
| Onset | <0.001 | ||||
| ≤10 min | 247 (62.7%) | 552 (57.4%) | 832 (77.1%) | 175 (74.2%) | |
| >10 min | 147 (37.3%) | 410 (42.6%) | 247 (22.9%) | 61 (25.8%) | |
| Setting | <0.001 | ||||
| Inpatients | 167 (42.2%) | 308 (32.0%) | 437 (40.5%) | 103 (43.6%) | |
| Outpatients/DH | 122 (31.0%) | 487 (50.6%) | 539 (50.0%) | 102 (43.2%) | |
| Hospice/Home palliative care | 105 (26.6%) | 167 (17.4%) | 103 (9.5%) | 31 (13.1%) | |
| Cancer type | <0.001 | ||||
| Lung | 67 (17.0%) | 232 (24.1%) | 298 (27.6%) | 68 (28.8%) | |
| Gastric | 104 (26.4%) | 173 (18.0%) | 161 (14.9%) | 31 (13.1) | |
| Breast | 41 (10.4%) | 110 (11.4%) | 104 (9.6%) | 23 (9.7%) | |
| Pancreatic | 38 (9.6%) | 80 (8.3%) | 101 (9.4%) | 18 (7.6%) | |
| Uro-gynecological | 42 (10.7%) | 146 (15.2%) | 172 (15.9%) | 41 (17.4%) | |
| All other cancers | 102 (25.9%) | 407 (42.5%) | 459 (42.5%) | 101 (42.8%) | |
| Therapy | 0.008 | ||||
| None | 65 (16.5%) | 150 (15.6%) | 132 (12.2%) | 19 (8.1%) | |
| ROOs | 175 (44.4%) | 441 (45.8%) | 553 (51.3%) | 133 (56.4%) | |
| Morphine ° | 91 (23.1%) | 182 (18.9%) | 211 (19.6%) | 43 (18.2%) | |
| Other therapies | 63 (16%) | 200 (20.8%) | 183 (17%) | 41 (17.4%) | |
* Chi-square test. Abbreviations: RT—radiotherapy; DH—day hospital; ROOs—rapid-onset opioids. Legend: ° Orally morphine sulfate, morphine hydrochloride subcutaneous or intravenous.